Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical pirfenidone for localized scleroderma
IRCT20150721023282N29Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of pirfenidone in morphea (2 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoints: Change in Modified Localized Scleroderma Severity Index score, Change in Physician Global Assessment and 1 more. Started May 2025; status: completed.
02
Drugs
pirfenidone
03
Conditions
morphea
Beyond the preview
Go deeper on IRCT20150721023282N29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20150721023282N29.